119 related articles for article (PubMed ID: 37154851)
1. Correction to: CD33 BiTE
Marcinek A; Brauchle B; Rohrbacher L; Hänel G; Philipp N; Märkl F; Strzalkowski T; Lacher SM; Udiljak D; Spiekermann K; Theurich S; Kobold S; Kischel R; James JR; Bücklein VL; Subklewe M
Cancer Immunol Immunother; 2023 Jul; 72(7):2513-2514. PubMed ID: 37154851
[No Abstract] [Full Text] [Related]
2. CD33 BiTE
Marcinek A; Brauchle B; Rohrbacher L; Hänel G; Philipp N; Märkl F; Strzalkowski T; Lacher SM; Udiljak D; Spiekermann K; Theurich S; Kobold S; Kischel R; James JR; Bücklein VL; Subklewe M
Cancer Immunol Immunother; 2023 Jul; 72(7):2499-2512. PubMed ID: 37041225
[TBL] [Abstract][Full Text] [Related]
3. Bifunctional PD-1 × αCD3 × αCD33 fusion protein reverses adaptive immune escape in acute myeloid leukemia.
Herrmann M; Krupka C; Deiser K; Brauchle B; Marcinek A; Ogrinc Wagner A; Rataj F; Mocikat R; Metzeler KH; Spiekermann K; Kobold S; Fenn NC; Hopfner KP; Subklewe M
Blood; 2018 Dec; 132(23):2484-2494. PubMed ID: 30275109
[TBL] [Abstract][Full Text] [Related]
4. Blockade of the PD-1/PD-L1 axis augments lysis of AML cells by the CD33/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism.
Krupka C; Kufer P; Kischel R; Zugmaier G; Lichtenegger FS; Köhnke T; Vick B; Jeremias I; Metzeler KH; Altmann T; Schneider S; Fiegl M; Spiekermann K; Bauerle PA; Hiddemann W; Riethmüller G; Subklewe M
Leukemia; 2016 Feb; 30(2):484-91. PubMed ID: 26239198
[TBL] [Abstract][Full Text] [Related]
5. CD33/CD3-bispecific T-cell engaging (BiTE®) antibody construct targets monocytic AML myeloid-derived suppressor cells.
Jitschin R; Saul D; Braun M; Tohumeken S; Völkl S; Kischel R; Lutteropp M; Dos Santos C; Mackensen A; Mougiakakos D
J Immunother Cancer; 2018 Nov; 6(1):116. PubMed ID: 30396365
[TBL] [Abstract][Full Text] [Related]
6. Immune therapies in acute myeloid leukemia: a focus on monoclonal antibodies and immune checkpoint inhibitors.
Assi R; Kantarjian H; Ravandi F; Daver N
Curr Opin Hematol; 2018 Mar; 25(2):136-145. PubMed ID: 29206680
[TBL] [Abstract][Full Text] [Related]
7. [Preparation of CD33 targeted bispecific- and trispecific-T cell engagers and their cytotoxicity on leukemia cells].
Zhang T; Chen ML; Liu XY; He HZ; Xu YX; Tian Z; Xing HY; Tang KJ; Rao Q; Wang M; Wang JX
Zhonghua Xue Ye Xue Za Zhi; 2022 May; 43(5):376-382. PubMed ID: 35680594
[No Abstract] [Full Text] [Related]
8. T-cell ligands modulate the cytolytic activity of the CD33/CD3 BiTE antibody construct, AMG 330.
Laszlo GS; Gudgeon CJ; Harrington KH; Walter RB
Blood Cancer J; 2015 Aug; 5(8):e340. PubMed ID: 26295610
[TBL] [Abstract][Full Text] [Related]
9. Preclinical characterization of AMG 330, a CD3/CD33-bispecific T-cell-engaging antibody with potential for treatment of acute myelogenous leukemia.
Friedrich M; Henn A; Raum T; Bajtus M; Matthes K; Hendrich L; Wahl J; Hoffmann P; Kischel R; Kvesic M; Slootstra JW; Baeuerle PA; Kufer P; Rattel B
Mol Cancer Ther; 2014 Jun; 13(6):1549-57. PubMed ID: 24674885
[TBL] [Abstract][Full Text] [Related]
10. The Broad Anti-AML Activity of the CD33/CD3 BiTE Antibody Construct, AMG 330, Is Impacted by Disease Stage and Risk.
Harrington KH; Gudgeon CJ; Laszlo GS; Newhall KJ; Sinclair AM; Frankel SR; Kischel R; Chen G; Walter RB
PLoS One; 2015; 10(8):e0135945. PubMed ID: 26305211
[TBL] [Abstract][Full Text] [Related]
11. Characterization of a Novel FLT3 BiTE Molecule for the Treatment of Acute Myeloid Leukemia.
Brauchle B; Goldstein RL; Karbowski CM; Henn A; Li CM; Bücklein VL; Krupka C; Boyle MC; Koppikar P; Haubner S; Wahl J; Dahlhoff C; Raum T; Rardin MJ; Sastri C; Rock DA; von Bergwelt-Baildon M; Frank B; Metzeler KH; Case R; Friedrich M; Balazs M; Spiekermann K; Coxon A; Subklewe M; Arvedson T
Mol Cancer Ther; 2020 Sep; 19(9):1875-1888. PubMed ID: 32518207
[TBL] [Abstract][Full Text] [Related]
12. Clinical overview of anti-CD19 BiTE(®) and ex vivo data from anti-CD33 BiTE(®) as examples for retargeting T cells in hematologic malignancies.
Zugmaier G; Klinger M; Schmidt M; Subklewe M
Mol Immunol; 2015 Oct; 67(2 Pt A):58-66. PubMed ID: 25883042
[TBL] [Abstract][Full Text] [Related]
13. The inhibitory effect of anti-CD33 monoclonal antibodies on AML cell growth correlates with Syk and/or ZAP-70 expression.
Balaian L; Zhong RK; Ball ED
Exp Hematol; 2003 May; 31(5):363-71. PubMed ID: 12763134
[TBL] [Abstract][Full Text] [Related]
14. CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330.
Krupka C; Kufer P; Kischel R; Zugmaier G; Bögeholz J; Köhnke T; Lichtenegger FS; Schneider S; Metzeler KH; Fiegl M; Spiekermann K; Baeuerle PA; Hiddemann W; Riethmüller G; Subklewe M
Blood; 2014 Jan; 123(3):356-65. PubMed ID: 24300852
[TBL] [Abstract][Full Text] [Related]
15. Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML.
Laszlo GS; Gudgeon CJ; Harrington KH; Dell'Aringa J; Newhall KJ; Means GD; Sinclair AM; Kischel R; Frankel SR; Walter RB
Blood; 2014 Jan; 123(4):554-61. PubMed ID: 24311721
[TBL] [Abstract][Full Text] [Related]
16. T lymphocytes can be effectively recruited for ex vivo and in vivo lysis of AML blasts by a novel CD33/CD3-bispecific BiTE antibody construct.
Aigner M; Feulner J; Schaffer S; Kischel R; Kufer P; Schneider K; Henn A; Rattel B; Friedrich M; Baeuerle PA; Mackensen A; Krause SW
Leukemia; 2013 Apr; 27(5):1107-15. PubMed ID: 23178753
[TBL] [Abstract][Full Text] [Related]
17. A Unique Human Immunoglobulin Heavy Chain Variable Domain-Only CD33 CAR for the Treatment of Acute Myeloid Leukemia.
Schneider D; Xiong Y; Hu P; Wu D; Chen W; Ying T; Zhu Z; Dimitrov DS; Dropulic B; Orentas RJ
Front Oncol; 2018; 8():539. PubMed ID: 30524966
[TBL] [Abstract][Full Text] [Related]
18. A novel C2 domain binding CD33xCD3 bispecific antibody with potent T-cell redirection activity against acute myeloid leukemia.
Nair-Gupta P; Diem M; Reeves D; Wang W; Schulingkamp R; Sproesser K; Mattson B; Heidrich B; Mendonça M; Joseph J; Sendecki J; Foulk B; Chu G; Fink D; Jiao Q; Wu SJ; Packman K; Elsayed Y; Attar R; Gaudet F
Blood Adv; 2020 Mar; 4(5):906-919. PubMed ID: 32150609
[TBL] [Abstract][Full Text] [Related]
19. Biting back: BiTE antibodies as a promising therapy for acute myeloid leukemia.
Walter RB
Expert Rev Hematol; 2014 Jun; 7(3):317-9. PubMed ID: 24617311
[TBL] [Abstract][Full Text] [Related]
20. Siglec-5 is an inhibitory immune checkpoint molecule for human T cells.
Vuchkovska A; Glanville DG; Scurti GM; Nishimura MI; White P; Ulijasz AT; Iwashima M
Immunology; 2022 Jun; 166(2):238-248. PubMed ID: 35290663
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
